PYC Therapeutics appoints experienced US biotech executive to its board

Latest News

PYC Therapeutics (ASX:PYC), a biotechnology company developing precision RNA therapeutics, has announced the appointment of Dr Michael Rosenblatt to its board of directors.

Dr Rosenblatt is a senior partner at Flagship Pioneering and the former chief medical officer of MSD. In his current role at Flagship, he has helped launch several biotechnology companies, including providing counsel on clinical development strategies and chairing or serving on their scientific or clinical advisory committees. He currently serves on the board of the Flagship companies Rubius Therapeutics, Cygnal Therapeutics and Ohana Biosciences.

He also brings expertise in the development of RNA therapeutics through his current role as a member of Moderna Therapeutics’ Development Committee of the Board and Vaccine Acceleration Committee and as a consultant to Moderna’s Chief Medical Officer.

“We are honoured to welcome Dr Rosenblatt as the first US member of PYC’s Board of Directors,” said Sahm Nasseri, US CEO of PYC Therapeutics.

“As a visionary, accomplished life science leader who has led or served on the board of numerous innovative healthcare companies, Michael brings a wealth of knowledge and expertise at this pivotal period of growth and scientific advancement at our organization. We welcome his strategic guidance as we advance our pipeline of multiple development candidates closer to the clinic.”

“PYC’s novel approach to delivering RNA therapeutics using naturally-derived cell-penetrating peptides shows great promise for improving clinical outcomes for patients with inherited diseases,” said Dr Rosenblatt.

“I look forward to working with the entire PYC team to advance this innovative technology into the clinic to further elucidate its full potential in a range of applications.”

Dr Rosenblatt joined Flagship from MSD, where he served as executive vice president and chief medical officer from 2009 to 2016. In an earlier period at MSD, he led drug discovery efforts in ophthalmology, molecular biology, bone biology, virology, cancer research, gastroenterology, lipid metabolism and cardiovascular research.